13 February 2015

Monica A. Konerman, Yiwei Zhang, Ji Zhu, Peter D.R. Higgins, Anna S.F. Lok, Akbar K. Waljee – 12 February 2015 – Existing predictive models of risk of disease progression in chronic hepatitis C have limited accuracy. The aim of this study was to improve upon existing models by applying novel statistical methods that incorporate longitudinal data. Patients in the Hepatitis C Antiviral Long‐term Treatment Against Cirrhosis trial were analyzed.

Hsi‐Hsun Lin, Susan Shin‐Jung Lee, Ming‐Lung Yu, Ting‐Tsung Chang, Chien‐Wei Su, Bor‐Shen Hu, Yaw‐Sen Chen, Chun‐Kai Huang, Chung‐Hsu Lai, Jiun‐Nong Lin, Jaw‐Ching Wu – 11 February 2015 – The emergence of hepatitis D virus (HDV) infection in the era of widespread HBV vaccination has not been described before. We aimed to investigate the changing epidemiology of HDV infection among high‐ and low‐risk populations after an outbreak of human immunodeficiency virus (HIV) infection among injection drug users (IDUs) in Taiwan.

Jean‐Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, Mohand Ait Ahmed, Setty Allam, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean‐Pierre Bronowicki, Jean‐Pierre Zarski, Odile Goria, Paul Calès, Jean‐Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean‐Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean‐Didier Grangé, Catherine Buffet, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christ

Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong‐Won Park, Jijin Yang, Lunan Yan, Myron Schwartz, Guohong Han, Francesco Izzo, Mishan Chen, Jean‐Frédéric Blanc, Philip Johnson, Masatoshi Kudo, Lewis R. Roberts, Morris Sherman – 11 February 2015 – Current guidelines recommend surgical resection as the primary treatment for a single hepatocellular cancer (HCC) with Child's A cirrhosis, normal serum bilirubin, and no clinically significant portal hypertension. We determined how frequently guidelines were followed and whether straying from them impacted survival.

Andrew J. Leidner, Harrell W. Chesson, Fujie Xu, John W. Ward, Philip R. Spradling, Scott D. Holmberg – 11 February 2015 – New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. This study investigated the cost‐effectiveness of these treatments with a focus on patients in early stages of liver disease.

Didac Carmona‐Gutierrez, Andreas Zimmermann, Frank Madeo – 11 February 2015

James L. Boyer – 11 February 2015

Nisanne S. Ghonem, David N. Assis, James L. Boyer – 11 February 2015 – Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. If left untreated, cholestasis leads to liver fibrosis and cirrhosis, which eventually results in liver failure and the need for liver transplantation.

Nisanne S. Ghonem, David N. Assis, James L. Boyer – 11 February 2015 – Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. If left untreated, cholestasis leads to liver fibrosis and cirrhosis, which eventually results in liver failure and the need for liver transplantation.